Nomogram predicts venous thromboembolism in glioma patients
The team, led by Chuanhao Zhang from Capital Medical University in Beijing...Read more on AuntMinnie.comRelated Reading:
Nomogram assesses lymph node status better in early breast cancer
Quantitative ultrasound data could help predict preterm births
Wearable ultrasound patch collects cardiac images
Researchers develop ultrasound 'tornado' technique to treat blood clots
Combined AI system on par with radiologists for detecting breast cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 13, 2023 Category: Radiology Source Type: news
Early DAPT Improves Outcomes for Strokes With No Other Tx Options
(MedPage Today) -- DALLAS -- Adding tirofiban (Aggrastat) to aspirin for dual antiplatelet therapy (DAPT) within 24 hours of acute ischemic stroke improved outcomes for patients who weren't candidates for thrombolytic or endovascular treatment... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 12, 2023 Category: Cardiology Source Type: news
Tirofiban Improves Outcomes for Strokes With No Other Tx Options
(MedPage Today) -- DALLAS -- Tirofiban (Aggrastat) improved acute ischemic stroke outcomes for patients who weren't candidates for thrombolytic or endovascular treatment, according to a phase III trial from China.
The glycoprotein IIb/IIIa inhibitor... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 11, 2023 Category: Cardiology Source Type: news
Lessons From Flint, Mich. on Stroke Preparedness and Lytic Uptake
(MedPage Today) -- DALLAS -- Efforts to boost stroke treatment in Flint, Michigan had mixed results that nevertheless left the community with one of the highest thrombolytic usage rates in the state, even amid a public health crisis, according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 10, 2023 Category: American Health Source Type: news
A case of early pulmonary embolism following blunt trauma to chest and a long bone fracture: a case report - Thivaharan Y, Dayapala A, Thanushan M.
BACKGROUND: After substantial trauma, pulmonary embolism (PE) carries a high risk of morbidity and mortality. Early post-traumatic PE in the absence of deep vein thrombosis (DVT) is a distinct entity that might be connected to rare mechanisms or unidentifi... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
A 'large number’ of blood clot patients report the same problem within 'weeks' or 'months'
Postphlebitic syndrome, reported by up to 50 percent of patients with deep vein thrombosis , can cause problems when standing or walking. (Source: Daily Express - Health)
Source: Daily Express - Health - February 1, 2023 Category: Consumer Health News Source Type: news
European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Investor Update - February 1, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Media News - February 1, 2023 Category: Pharmaceuticals Source Type: news
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
PONTE VEDRA, Fla., Jan. 23, 2023 -- (Healthcare Sales & Marketing Network) -- Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, anno... Biopharmaceuticals, FDA Cadrenal Therapeutics, tecarfarin, thromboembolism, ESRD , AFib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2023 Category: Pharmaceuticals Source Type: news
Risk of thromboembolism in patients with COVID19 who are using hormonal contraception, Cochrane Library
Authors ' conclusions There are no comparative studies assessing risk of thromboembolism in COVID ‐19 patients who use hormonal contraception, which was the primary objective of this review. Very little evidence exists examining the risk of increased COVID‐19 disease severity for combined hormonal contraception users compared to non‐users of hormonal contraception, and the evidence that do es exist is of very low certainty. The odds of hospitalization for COVID‐19 positive users of combined hormonal contraceptives may be slightly decreased compared with those of hormonal contraceptive non‐users, but the evidence ...
Source: Current Awareness Service for Health (CASH) - January 20, 2023 Category: Consumer Health News Source Type: news
Risk of thromboembolism in patients with COVID19 who are using hormonal contraception
Very little evidence exists on risk of VTE or increased COVID ‐19 severity for users of combined hormonal contraception (HC) vs. non‐users. Low certainty evidence suggests use of any HC method vs no contraceptive has little/no effect on hospitalization, intubation, or mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 13, 2023 Category: Consumer Health News Source Type: news
In Diabetes, Women Have Higher Risk for Venous Thromboembolism
THURSDAY, Jan. 5, 2023 -- Individuals with diabetes mellitus (DM), especially women, have an increased risk for venous thromboembolism (VTE), according to a study published in the December issue of Diabetes Research and Clinical Practice.
Carola... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2023 Category: Pharmaceuticals Source Type: news
Which DOAC Is Cost-Effective in Cancer-Associated Thrombosis? Which DOAC Is Cost-Effective in Cancer-Associated Thrombosis?
Until recently, clinicians had little evidence to guide their decisions about the most effective and safe treatment for the oldest patients with atrial fibrillation and recent stroke.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 4, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Letter re: Racial disparities in administration of VTE prophylaxis after severe traumatic injuries - Sarani B, Mohseni S.
The authors would like to thank Dr. Breeding and colleagues for their interest in our paper "Racial Disparities in Administration of Venous Thromboembolism (VTE) Prophylaxis After Severe Traumatic Injuries"1 and their valuable comments.
The main object... (Source: SafetyLit)
Source: SafetyLit - January 4, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
DOACs vs Heparin in Cancer-Associated Thrombosis DOACs vs Heparin in Cancer-Associated Thrombosis
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
